Immuneering (IMRX) Non Operating Investment Income (2021 - 2022)
Immuneering (IMRX) posted quarterly Non Operating Investment Income of $112353.0 for Q4 2022, up 353.86% year-over-year from $24755.0 in Q4 2021, and up 187.44% quarter-over-quarter from $39088.0 in Q3 2022.
Powered by 
Analysis
Immuneering (IMRX) Non Operating Investment Income (2021 - 2022) Analysis & Trends
Immuneering's Non Operating Investment Income history runs 2 years deep, the most recent figure standing at $112353.0 for Q4 2022.
- In Q4 2022, Non Operating Investment Income rose 353.86% year-over-year to $112353.0; the TTM figure through Dec 2022 stood at $18889.0 (changed N/A YoY), while the FY2022 annual figure was $18889.0, up 138.54% from the prior year.
- Non Operating Investment Income for Q4 2022 stood at $112353.0, up from $39088.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $112353.0 in Q4 2022, with the low at -$118386.0 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Immuneering | 316.05 Mn | 316.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 112,353.00 |
| Sep 30, 2022 | 39,088.00 |
| Jun 30, 2022 | -14,166.00 |
| Mar 31, 2022 | -118,386.00 |
| Dec 31, 2021 | -44,258.00 |
| Sep 30, 2021 | -4,751.00 |